Irbesartan

厄贝沙坦

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameIrbesartan
Drug Alias Name伊贝沙坦XarbIrbesartanum依贝沙坦Aprovel +[13
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsStress, PsychologicalObesityHypercholesterolemia +[16
Global Approved IndicationsHypertensionDiabetic Nephropathies
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryEU
Original Approved Date1997/08/26
Country/TerritoryCzechiaBelgiumCanada +[35
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active IndicationsHypertensionDiabetic NephropathiesEsophageal Diseases
Inactive IndicationsStress, PsychologicalObesityHypercholesterolemia +[13

Other Information

ATC CodeC09CA04